$1.57 Billion is the total value of Eversept Partners, LP's 107 reported holdings in Q4 2021. The portfolio turnover from Q3 2021 to Q4 2021 was 100.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| FREQ | Exit | FREQUENCY THERAPEUTICS INC | $0 | – | -30,000 | -100.0% | -0.02% | – |
| CCRN | Exit | CROSS CTRY HEALTHCARE INC | $0 | – | -20,000 | -100.0% | -0.03% | – |
| Exit | TELIGENT INC NEW | $0 | – | -1,069,465 | -100.0% | -0.03% | – | |
| FREQ | Exit | FREQUENCY THERAPEUTICS INCput | $0 | – | -67,900 | -100.0% | -0.03% | – |
| DCPH | Exit | DECIPHERA PHARMACEUTICALS INcall | $0 | – | -18,700 | -100.0% | -0.04% | – |
| PHAS | Exit | PHASEBIO PHARMACEUTICALS INC | $0 | – | -300,000 | -100.0% | -0.06% | – |
| AMN | Exit | AMN HEALTHCARE SVCS INC | $0 | – | -10,000 | -100.0% | -0.08% | – |
| AKYA | Exit | AKOYA BIOSCIENCES INC | $0 | – | -91,568 | -100.0% | -0.09% | – |
| MGTA | Exit | MAGENTA THERAPEUTICS INC | $0 | – | -198,879 | -100.0% | -0.10% | – |
| EDIT | Exit | EDITAS MEDICINE INCput | $0 | – | -50,000 | -100.0% | -0.14% | – |
| NVAX | Exit | NOVAVAX INCcall | $0 | – | -10,000 | -100.0% | -0.14% | – |
| HSTM | Exit | HEALTHSTREAM INC | $0 | – | -77,812 | -100.0% | -0.15% | – |
| OM | Exit | OUTSET MED INC | $0 | – | -47,500 | -100.0% | -0.16% | – |
| MORF | Exit | MORPHIC HLDG INC | $0 | – | -43,600 | -100.0% | -0.17% | – |
| EVH | Exit | EVOLENT HEALTH INCcl a | $0 | – | -100,170 | -100.0% | -0.22% | – |
| APLS | Exit | APELLIS PHARMACEUTICALS INCcall | $0 | – | -126,400 | -100.0% | -0.29% | – |
| HRC | Exit | HILL-ROM HLDGS INCcall | $0 | – | -29,400 | -100.0% | -0.31% | – |
| HRC | Exit | HILL-ROM HLDGS INC | $0 | – | -30,000 | -100.0% | -0.31% | – |
| GOCO | Exit | GOHEALTH INC | $0 | – | -1,261,723 | -100.0% | -0.44% | – |
| MASI | Exit | MASIMO CORP | $0 | – | -67,000 | -100.0% | -1.26% | – |
| CTLT | Exit | CATALENT INC | $0 | – | -184,299 | -100.0% | -1.70% | – |
| BMY | Exit | BRISTOL-MYERS SQUIBB CO | $0 | – | -464,801 | -100.0% | -1.93% | – |
| SPY | Exit | SPDR S&P 500 ETF TRput | $0 | – | -100,000 | -100.0% | -2.98% | – |
| XLRN | Exit | ACCELERON PHARMA INC | $0 | – | -349,494 | -100.0% | -4.18% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| AMARIN CORP PLC | 21 | Q3 2023 | 12.5% |
| DANAHER CORPORATION | 21 | Q3 2023 | 8.1% |
| AFFIMED N V | 20 | Q3 2023 | 0.9% |
| ARGENX SE | 19 | Q3 2023 | 2.0% |
| GSK PLC | 18 | Q2 2022 | 13.1% |
| ASCENDIS PHARMA A/S | 18 | Q1 2022 | 7.7% |
| SANOFI | 18 | Q4 2022 | 7.2% |
| ENSIGN GROUP INC | 18 | Q1 2022 | 8.6% |
| CENTENE CORP DEL | 18 | Q3 2023 | 1.5% |
| ZOGENIX INC | 17 | Q4 2021 | 12.4% |
View Eversept Partners, LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Cabaletta Bio, Inc. | February 14, 2023 | 282,874 | 1.0% |
| Teligent, Inc.Sold out | February 16, 2021 | 0 | 0.0% |
| Teligent, Inc. | February 14, 2020 | 4,501,799 | 8.4% |
View Eversept Partners, LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR/A | 2023-11-08 |
| 13F-HR/A | 2023-11-08 |
| 13F-HR/A | 2023-11-08 |
| 13F-HR/A | 2023-11-08 |
| 13F-HR/A | 2023-11-08 |
| 13F-HR/A | 2023-11-08 |
| 13F-HR/A | 2023-11-08 |
View Eversept Partners, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.